Detection of *Mycobacterium Tuberculosis* Multiple Strains in Sputum Samples from Patients with Pulmonary Tuberculosis in South Western Uganda using MIRU-VNTR

Lisa Nkatha Micheni (✉ lisa.micheni@kiu.ac.ug)

Mbarara University of Science and Technology

Kennedy Kassaza

Mbarara University of Science and Technology

Hellen Kinyi

Kabale University

Ibrahim Ntulume

Kampala International University Western Campus

Joel Bazira

Mbarara University of Science and Technology

Research Article

Keywords: Mycobacterium tuberculosis, sputum samples , pulmonary tuberculosis

Posted Date: September 9th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-835598/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on January 31st, 2022. See the published version at <https://doi.org/10.1038/s41598-022-05591-3>.

Abstract

Infections with multiple strains of *Mycobacterium tuberculosis* are now widely recognized as a common occurrence. Identification of patients infected with multiple strains, provides both insight into the disease dynamics and the epidemiology of tuberculosis. Analysis of Mycobacterial Interspersed Repetitive Unit-Variable-Number Tandem Repeats (MIRU-VNTR) has been shown to be highly sensitive in detecting multiple *M. tuberculosis* strains even in sputum. The goal of this study was to identify cases of multiple *M. tuberculosis* strain infections among patients with pulmonary tuberculosis in south western Uganda and factors associated with multiple strain infections. Seventy-eight sputum samples were analyzed using the standard 24 loci MIRU-VNTR typing and an exact regression analysis performed using Stata version 14. Five (6.4%) of the 78 patients were infected with multiple strains of *M. tuberculosis*. All of the patients infected with multiple strains were the newly diagnosed cases while one third of them were co-infected with HIV. These findings point to a critical component of disease dynamics that is most likely being overlooked at the clinical level, emphasizing the need to further study the potential high risk of exposure to these categories of patients at the community level using a larger sample size.

Introduction

Mycobacterium tuberculosis (MTB) is one of the world's most successful human pathogen that has survived for millennia. It is associated with high morbidity and mortality worldwide, with over 1.5 million fatalities and 10 million new cases being recorded each year, making it the leading cause of death due to a single infectious agent worldwide ¹⁻³. These infections are as a result of either a primary infection, an endogenous reactivation of a primary infection or exogenous re-infection with a new strain ⁴. Historically, it was presumed that tuberculosis (TB) was as a result of a single strain and any recurrence was assumed to be due to reactivation of the same strain that caused the first episode ⁵. Infection due to multiple strains in a patient at a single point in time was barely considered. However, in the mid-1970s using phage typing, it was discovered that different strains of MTB can infect a patient at the same time ⁶ either as a result of a single transmission involving multiple distinct strains or due to multiple transmission events ⁷. Moreover, distinguishing multiple strain infections from clonal diversity is essential because there is a significant difference in how these two mechanisms generate within-host diversity. Clonal diversity involves sporadic polymorphism due to sequential adaptive mutations (microevolutions) ⁸⁻¹⁰, whereas multiple infections involve a host acquiring an entirely new MTB genome through successive or concurrent exposure to different strains ^{11,12}. Considering that members of *Mycobacterium tuberculosis* complex (MTBC) have highly conserved genomes ^{13,14}, high quality methods are required to identify small alterations within the infecting mycobacterial population. So far, various Polymerase Chain Reaction (PCR) based approaches have been utilized to demonstrate multiple strains within the same sputum sample ^{10,15} or different sputum samples from the same patient ^{8,16}. Mycobacterial Interspersed Repetitive Units-variable Number of Tandem Repeats (MIRU-VNTR) analysis identifies such changes in the genome by varying the copy of repeats in highly variable regions of the MTBC genome ^{17,18}.

This study aimed at identifying multiple MTB strain infections among patients with pulmonary tuberculosis (PTB) in a high TB incidence area using MIRU-VNTR analysis and determining factors that could be associated with mixed infections in this area. TB incidence in south western Uganda is high at 253 cases per 100 000 people per year ^{19,20}. It has been shown that multiple MTB strain infections are more common among people living in high TB burdened areas ^{4,7,11,21} and accurate identification of this condition provides not only insight into the disease trends but also helps in the management and control of TB ^{16,22-25}.

Results

Prevalence of multiple strains infection

MIRU-VNTR typing was performed on 78 sputum samples, each from an individual PTB patient. Majority of these samples (91%;71/78) were from newly diagnosed cases while 9% (7/78) were relapse patients. Ten (12.8%) patients were from refugees residing in the resettlement camps, 6 (7.7%) were from patients in prison. According to the HIV status records, 39.7% (31/78), 24.4% (19/78), and 35.9% (28/78) were HIV positive, negative or unknown respectively (Table 1). Five of the 78 (6.4%) patients were found to be infected with more than one strain of *M. tuberculosis* with all cases of multiple strain infections being the newly diagnosed patients. Three patients infected with multiple strains were men while the same number were HIV positive (Table 1).

One patient (#63) had strains belonging to two different lineages that also showed resistance to isoniazid while the rest belonged to the same lineage (see Table 2 and Fig. 1).

Table 1

Prevalence of *M. tuberculosis* multiple infections and comparison between patients with multiple versus single strain infections in Southwestern, Uganda

Variable	Category	Patient's characteristics n (%)	Single Strain (n = 73; 93.6%); 95% CI (0.864–0.976)	Multiple strains (n = 5; 6.4%); 95% CI (0.024–0.136)	χ^2 p-value
Age	18–24	57 (73.1)	53 (93.0)	4 (7.0)	0.799
	25–44	15 (19.2)	14 (93.3)	1 (6.7)	
	45–64	6 (7.7)	6 (100)	0 (0)	
Gender	Male	63 (80.8)	60 (95.2)	3 (4.8)	0.223
	Female	15 (19.2)	13 (86.7)	2 (13.3)	
HIV status	Positive	31 (39.7)	28 (90.3)	3 (9.7)	0.616
	Negative	19 (24.4)	18 (94.7)	1 (5.3)	
	Unknown	28 (35.9)	27 (96.4)	1 (3.6)	
Level of Income	High	7 (9.0)	7 (100)	0 (0.0)	0.468
	Low	71 (91.0)	66 (93.0)	5 (7.0)	
TB in the past	No	71 (91.0)	66 (93.0)	5 (7.0)	0.468
	Yes	7 (9.0)	7 (100)	0 (0)	
Refugee status	No	68 (87.2)	63 (92.6)	5 (7.4)	0.375
	Yes	10 (12.8)	10 (100)	0 (0.0)	
Imprisoned	No	72 (92.3)	67 (93.1)	5 (6.9)	0.505
	Yes	6 (7.7)	6 (100)	0 (0.0)	
Rif resistance	No	63 (80.8)	58 (92.1)	5 (7.9)	0.259
	Yes	15 (19.2)	15 (100)	0 (0.0)	
Inh resistance	No	63 (80.8)	67 (94.4)	4 (5.6)	0.373
	Yes	15 (19.2)	6 (85.7)	1 (14.3)	
Statistical significance considered at p-value ≤ 0.05					

Table 2

Patients' in south western Uganda harboring more than one strain of *M. tuberculosis* identified using MIRU-VNTR standardized 24 loci

MIRU-VNTR loci																								
ID	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
63	2	2	4,5	2	3	2	2	3	1,2	4	2	4	2	2	5	1	5	3	3	4	2	4	2	2
202	2	2,3	4	2	3	3	2,3	3	1	2	4	4	2	1	5	1	4	3	3	2,3	3	7	2	2
228	2	2,3,4	4	6	3	4	2	5	2	2	7	3	2	4	5	2	2	3	3	2	2,5	6	1	3
2264	2	3	5	2	3	7	2	3	2	2	4	4	4	2	5	1	1	3	2,3,4	2,3	3	6	3	2
10546	2	3	5	2	2	3	3	3	1,2	2	4	4	2	2	5	1	5	3	2,3	3	2,5	6	2	2
The numerical figures represent the number of alleles per amplified MIRU-VNTR loci, as described by Supply et al (Supply, 2005). Where there is more than one numerical figure per locus indicates existence of more than one MTB strain in the sample, signifying an infection with multiple strains of <i>M. tuberculosis</i> . MIRU-VNTR Loci: 1 = 154, 2 = 424, 3 = 577, 4 = 580, 5 = 802, 6 = 960, 7 = 1644, 8 = 1955, 9 = 2059, 10 = 2163b, 11 = 2165, 12 = 2347, 13 = 2401, 14 = 2461, 15 = 2531, 16 = 2687, 17 = 2996, 18 = 3007, 19 = 3171, 20 = 3192, 21 = 3690, 22 = 4052, 23 = 4156, 24 = 4348. ID = patient identification number																								

Exact regression analysis of factors associated with multiple strains infection

The conditional maximum likelihood from the bivariable exact regression revealed that none of the patients' demographic variables such as age, sex was linked to multiple strain infections (Table 3). However, due to the fact that the number of individuals with multiple strain infections is so small, drawing firm inferences from these findings is difficult.

Table 3
Exact bivariate logistic regression of factors associated with multiple strains of *M. tuberculosis* infections among PTB patients in Southwestern, Uganda

Characteristics	Odds ratio	95% CI	p-value
Age group (years)			
18–24	1.780	0-16.388	1.000
25–44	0.947	0.018–10.629	1.000
45–64	1.000		
Sex			
Female	3.020	0.231–29.260	0.488
Male	1.000		
HIV status			
Positive	2.843	0.213-157.389	0.691
Negative	1.487	0.018–122.040	1.000
Unknown	1.00		
Level of income			
Low	1.483*	0-12.483	1.000
High	1.000		
Incarceration			
No	1.767*	0-15.236	1.000
Yes	1.000		
Refugees			
No	0.981*	0-7.926	1.000
Yes	1.000		
TB in the past			
No	1.483	0-12.483	1.000
Yes	1.000		
Rif			
No	0.598*	0-4.693	0.666
Yes	1.000		
Inh			
No	2.740	0.049–34.662	0.767
Yes	1.000		
*Median unbiased estimates (MUE)			

Discussion

Multiple strain infections in TB are now recognized as common occurrences and identifying patients with multiple MTB strains is critical in clinical practice, public health and molecular epidemiology. This is because not only does it provide insight into the disease patterns but also aids in the management and control of TB. This study revealed that, one out of every sixteen PTB patients (6.4%) was infected with multiple strains of MTB. This prevalence is almost similar to the 7.1% reported in Kampala, Uganda ¹¹ but much lower than the 11% observed in Mubende, Uganda ²¹. It is probable that the disparities in estimations are due to discrepancies in sensitivities of the genotyping techniques used to differentiate between MTB strains. While there are diverse genotyping approaches employed in the identification of mixed infections, the degree of sensitivity of each method varies. While the Mubende and Kampala investigations used 15 loci MIRU-VNTR typing, our study used 24 loci MIRU-VNTR typing with a single target conventional PCR. This method has been demonstrated to be very sensitive and discriminative, rendering it the gold standard in the diagnosis of multiple strain infections ^{31,32}. Other significant discrepancies can be seen in the laboratory methods utilized. As with any other approach used to identify multiple strain infections,

detection of an underlying strain can only be established when there are sufficient DNA copies of that strain in the sample being studied. Many studies, including the Kampala and Mubende studies, use culture to increase the mycobacterial population ^{11,21,33}. However, this can drastically change the clonal composition thus changing the frequency with which multiple strains are detected ^{9,31,34}. In our study, we utilized DNA isolated directly from processed sputum samples. Our findings are also much higher than the 2.8% ¹² reported in Malawi and 3.2% in Zambia ³⁵ but lower than the 9.6% ³⁶ and 10% ³⁷ reported in Botswana. Differences between the study settings may partly account for this difference whereby the annual risk of TB infection in Malawi is approximately 1% ^{3,38} while in Botswana its 3% ³⁹.

Our study also revealed that unlike the relapse patients, who were not infected with multiple strains, all (100%) of the patients in our study with multiple strain infections were newly diagnosed cases. This is consistent with the findings of the Mubende study ²¹, which observed that the majority (87.5%) of patients with multiple strains were the newly diagnosed cases. This might reflect a high level of transmission and heterogeneity of strains in this category of patients (Cohen et al., 2012). This hypothesis is supported by the proportion of newly diagnosed cases that exhibited the multiple strain infection phenomena, an attribute that is reported to indicate high transmission rates ⁴⁰⁻⁴². Furthermore, a third (9.7%) of the patients with multiple strain infections were also HIV-infected. This finding is consistent with other studies, in which nearly all multiple strain TB infected people were HIV positive ^{11,21}. This appears to support the notion of the link between multiple strain TB infection and HIV/TB co-infection ^{16,21,36,43,44}. Given the high prevalence of HIV and HIV/TB co-infection in this region ⁴⁵, it is plausible to suggest that HIV-induced immune deficiency exposes patients to the risk of concurrent infections. HIV removes the security of being reinfected as one battles an ongoing infection there by creating a scenario where one can be infected even before they clear an ongoing infection (Elizabeth Glaser Foundation, 2015).

In conclusion, patients experiencing their initial episodes of the disease and those co-infected with HIV are more susceptible to being infected with multiple strains of *M. tuberculosis*. This points to a critical component of disease dynamics that is most likely being overlooked at the clinical level, emphasizing the need to further study the potential high risk of exposure to this category of patients at the community level.

Materials And Methods

Patients, sample collection and processing

All methods of this study were carried out in accordance with the approved guidelines. Sputum samples were collected from patients seeking health care at either Nakivale HC111, Kabale Regional Referral Hospital and Mbarara Regional Referral Hospital between May 2018 and April 2019. The patients were diagnosed with PTB using either Cepheid gene X-pert or Microscopy and enrolled in an ongoing epidemiological study in south western, Uganda, from which some papers have been published ²⁶. Samples were collected consecutively from patients who consented to the study upon completing an informed consent form and reported not having received treatment for TB in the preceding month. Patient demographics, sample processing and DNA extraction are described in Micheni et al (2021) ²⁶ while drug susceptibility testing is described in Micheni et al (2021). All samples were confirmed as MTB by PCR-detection of a 123 bp fragment of the IS6110, which is common in the members of the MTB complex

Ethical consideration

This study was approved by the Institutional Review Board of Mbarara University of Science and Technology (MUST-IRB), the Uganda National Council for Science and Technology (with UNCST reference number HS 2379). The health facility administrators and the prime minister, granted permission to access their facilities and refugee camps, respectively. A written informed consent was obtained from each patient who participated in the study.

Typing by MIRU-VNTR PCR

The MIRU-VNTR PCRs were performed on genomic DNA extracted from the sputum samples. Using primers specific for sequences flanking the MIRU units (Table 4), the PCR was designed to amplify a standard set of 24 MIRU-VNTR loci from genomic DNA retrieved from each sample.

Table 4

PCR primer sequences and MIRU-VNTR locus designations¹ used in this study

Loci	Alias	Repeating unit length (bp)	Primer sequences (5'-3')
580	MIRU4, ETRD	77	GCGCGAGAGCCCGAACTGC GCGCAGCAGAAACGTCCAGC
2996	MIRU26	51	CCCGCCTTCGAAACGTCGCT TGGACATAGGCGACCAGGCGAATA
802	MIRU40	54	GGGTTGCTGGATGACAACGTGT GGGTGATCTCGGCGAAATCAGATA
960	MIRU10	53	GTTCTTGACCAACTGCAGTCGTCC GCCACCTTGGTGATCAGCTACCT
1644	MIRU16	53	TCGGTGATCGGGTCCAGTCCAAGTA CCCGTCGTGCAGCCCTGGTAC
3192	MIRU31, ETR E	53	CTGATTGGCTTCATACGGCTTTA GTGCCGACGTGGTCTTGAT
424	Mtub04	51	GTCCAGGTTGCAAGAGATGG GGCATCCTCAAACAACGGTAG
577	ETR C	58	GACTTCAATGCGTTGTTGGA GTCTTGACCTCCACGAGTGC
2165	ETR A	75	ATTTTCGATCGGGATGTTGAT TCGGTCCCATCACCTTCTTA
2401	Mtub30	58	AGTCACCTTTCCTACCACTCGTAAC ATTAGTAGGGCACTAGCACCTCAAG
3690	Mtub39	58	AATCACGGTAACTTGGGTTGTTT GATGCATGTTTCGACCCGTAG
4156	QUB-4156	59	TGACCACGGATTGCTCTAGT GCCGGCGTCCATGTT
2163b	QUB-11b	69	CGTAAGGGGGATGCGGGAATAGG CGAAGTGAATGGTGGTGGCAT
1955	Mtub21	57	AGATCCCAGTTGTCGTCGTC CAACATCGCCTGGTTCTGTA
4052	QUB-26	111	GGCCAGGTCCCTCCCGAT AACGCTCAGCTGTCGGAT
154	MIRU 2	53	TGGAATTGCAGCAATGGACCAACT TACTCGGACGCCGGCTCAAAAT
2531	MIRU 23	53	CAGCGAAACGAACTGTGCTATCAC CGTGTCCGAGCAGAAAAGGGTAT
4348	MIRU 39	53	CGCATCGACAACTGGAGCCAAAC CGGAAACGTCTACGCCCCACACAT
2059	MIRU 20	77	TCGGAGAGATGCCCTTCGAGTTAG GGAGACCGCGACCAGGTACTTGTA
2687	MIRU 24	54	CGACCAAGATGTGCAGGAATACAT GGGCGAGTTGAGCTCACAGAA
3007	MIRU 27, QUB-5	53	TCGAAAGCCTCTGCGTGCCAGTAA GCGATGTGAGCGTGCCACTCAA

2461	ETR B, VNTR 48	57	GCGAACACCAGGACAGCATCATG GGCATGCCGGTGATCGAGTGG
2347	Mtub 29; VNTR 46	57	ATGATGGCACACCGAAGAAC AACCCATGTCAGCCAGGTTA
3171	Mtub 34; VNTR 49	54	GCAGATAACCCGCAGGAATA GGAGAGGATACGTGGATTGAG
¹ Extracted from Yasmin et al., ²⁷ . Primers were synthesized by Inqaba Biotec™ (South Africa).			

Each MIRU locus was amplified individually using a reaction mix and amplification profile described by Supply (2005)²⁸. For each reaction, DNA from *M. tuberculosis* H37Rv was used as a positive control, and sterile water was used as a negative control. Ten microliters of each PCR product were separated electrophoretically on 2% agarose gels for 3hrs, with a 100-bp DNA ladder (Solis Biotec™, Estonia) serving as size markers. The corresponding MIRU-VNTR bands in the gel images were reported as Roman numerals representing the number of repeats per loci as described in the protocol reference table by Supply (2005)²⁸. For any sample that revealed multiple bands at any of the MIRU loci, the PCR was repeated in order to confirm the results. Multiple strains were concluded as being present if a sample had double alleles at more than one locus while those samples that had varying copy numbers at a single locus were considered as single strain evolution rather than multiple strains.

Statistical analysis

Patients' biodata and the presence or absence of multiple strain infection results were entered and validated in Microsoft Excel® 2013. The data was then exported to Stata (Stata/SE 14.2 for windows, Stata Corp, College Station, TX) for statistical analysis. Chi-square test was used to compute proportions and determine the relationship between independent factors and dependent variables (presence multiple strain infection) with statistical significance considered at 95% level of confidence. Since the feature of interest (multiple strain infections) was found in a small number of patients, an exact bivariate logistic regression analysis was performed to obtain odds ratios for factors that could be associated with the occurrence of multiple strains of *M. tuberculosis* among PTB patients in our setting. Exact logistic regression was selected because it calculates the conditional maximum chance of an event occurring within the sample population described by the model's varying factors. We did not specify a statistical significance threshold in accordance with recent statistical guidelines^{29,30}.

Declarations

Acknowledgements

We gratefully acknowledge the technical help provided by the TB laboratory staff of Kabale and Mbarara regional referral hospitals, Nakivale health centre, and the Genomics and Translational laboratory of Mbarara University of Science and Technology.

Author contributions

LNM and JB designed and funded the study; LNM and KK collected the data; LNM, KK and IN conducted data analysis and interpretation. LNM, KK, IN, HK, JB interpreted results, wrote, revised the initial and final manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

References

1. WHO. Global Tuberculosis Report 2016. (World Health & Organization 2016). doi:10.16309/j.cnki.issn.1007-1776.2003.03.004.
2. WHO. Global Tuberculosis report 2018. (World Health & Organization 2018). doi:10.1177/2165079915607875.
3. WHO. *Global Tuberculosis Report 2019* (World Health Organization, 2019).
4. Mclvor, A., Koornhof, H. & Kana, B. D. Relapse, re-infection and mixed infections in tuberculosis disease. *Pathog. Dis.* **75**, 1–16 (2017).
5. Stead, W. W. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? *American Review of Respiratory Disease*, **95**, 729–745 (1967).
6. Bates, J. H., Stead, W. W. & Rado, T. A. Phage type of tubercle bacilli isolated from patients with two or more sites of organ involvement. *American Review of Respiratory Disease*, **114**, 353–358 (1976).
7. Tarashi, S., Fateh, A., Mirsaeidi, M., Siadat, S. D. & Vaziri, F. Mixed infections in tuberculosis: The missing part in a puzzle. *Tuberculosis*, **107**, 168–174 (2017).

8. Cohen, T., Wilson, D., Wallengren, K., Samuel, E. Y. & Murray, M. Mixed-strain *Mycobacterium tuberculosis* infections among patients dying in a Hospital in KwaZulu-Natal, South Africa. *J. Clin. Microbiol*, **49**, 385–388 (2011).
9. Martín, A. *et al.* The clonal composition of *Mycobacterium tuberculosis* in clinical specimens could be modified by culture. *Tuberculosis*, **90**, 201–207 (2010).
10. Shamputa, I. C. *et al.* Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. *Respir. Res*, **7**, 1–10 (2006).
11. Dickman, K. R. *et al.* Detection of multiple strains of *Mycobacterium tuberculosis* using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda. *BMC Infect. Dis.*, **10**, (2010).
12. Mallard, K. *et al.* Molecular detection of mixed infections of *Mycobacterium tuberculosis* strains in sputum samples from patients in Karonga District, Malawi. *J. Clin. Microbiol*, **48**, 4512–4518 (2010).
13. Manson, A. L. *et al.* Genomic analysis of globally diverse *Mycobacterium tuberculosis* strains provides insights into the emergence and spread of multidrug resistance. *Nat. Genet*, **49**, 395–402 (2017).
14. Gagneux, S. Genetic Diversity in *Mycobacterium tuberculosis*. *Curr. Top. Microbiol. Immunol*, **374**, 1–25 (2013).
15. Warren, R. M. *et al.* Patients with Active Tuberculosis often Have Different Strains in the Same Sputum Specimen. *Am. J. Respir. Crit. Care Med*, **169**, 610–614 (2004).
16. Cohen, T. *et al.* Mixed-strain *Mycobacterium tuberculosis* infections and the implications for tuberculosis treatment and control. *Clin. Microbiol. Rev*, **25**, 708–719 (2012).
17. Allix-Béguec, C., Harmsen, D., Weniger, T., Supply, P. & Niemann, S. Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of *Mycobacterium tuberculosis* complex isolates. *J. Clin. Microbiol*, **46**, 2692–2699 (2008).
18. Kremer, K. *et al.* Discriminatory power and reproducibility of novel DNA typing methods for *Mycobacterium tuberculosis* complex strains. *J. Clin. Microbiol*, **43**, 5628–5638 (2005).
19. Ministry of Health Uganda. *Annual Health Sector performance report 2015/16. UdhS* (2016) doi:10.1016/s0033-3506(17)80015-9.
20. Ministry of Health Uganda. *National Tuberculosis and Leprosy Division July 2017 – June 2018 Report*. vol. 48 (2018).
21. Muwonge, A. *et al.* Molecular investigation of multiple strain infections in patients with tuberculosis in Mubende district, Uganda. *Infect. Genet. Evol*, **17**, 16–22 (2013).
22. Zetola, N. M. *et al.* Clinical outcomes among persons with pulmonary tuberculosis caused by *Mycobacterium tuberculosis* isolates with phenotypic heterogeneity in results of drug-susceptibility tests. *J. Infect. Dis*, **209**, 1754–1763 (2014).
23. Sivanand Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis., **392**, 821–834 (2018).
24. Van Rie, A. *et al.* Reinfection and mixed infection cause changing *Mycobacterium tuberculosis* drug-resistance patterns. *Am. J. Respir. Crit. Care Med*, **172**, 636–642 (2005).
25. Kempker, R. R. *et al.* Acquired drug resistance in mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. *Emerg. Infect. Dis*, **21**, 992–1001 (2015).
26. Micheni, L. N., Kassaza, K., Kinyi, H., Ntulume, I. & Bazira, J. Diversity of *Mycobacterium tuberculosis* Complex Lineages Associated with Pulmonary Tuberculosis in Southwestern, Uganda. *Tuberc. Res. Treat.* 2021, 1–6 (2021).
27. Yasmin, M. *et al.* Quick and cheap MIRU-VNTR typing of *Mycobacterium tuberculosis* species complex using duplex PCR. *Tuberculosis*, **101**, 160–163 (2016).
28. Supply, P. Multilocus Variable Number Tandem Repeat Genotyping of *Mycobacterium tuberculosis*. *Inst. Pasteur Lille73* (2005).
29. Greenland, S. *et al.* Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. *Eur. J. Epidemiol*, **31**, 337–350 (2016).
30. Wasserstein, R. L. & Lazar, N. A. The ASA's Statement on p-Values: Context, Process, and Purpose. *Am. Stat*, **70**, 129–133 (2016).
31. Farmanfarmaei, G. *et al.* Bias in detection of *Mycobacterium tuberculosis* polyclonal infection: Use clinical samples or cultures? *Mol. Cell. Probes*, **33**, 1–3 (2017).
32. Bouklata, N. *et al.* Molecular typing of mycobacterium tuberculosis complex by 24-locus based MIRU-VNTR typing in conjunction with spoligotyping to assess genetic diversity of strains circulating in Morocco. *PLoS One*, **10**, 1–16 (2015).
33. Stavrum, R. *et al.* High diversity of *Mycobacterium tuberculosis* genotypes in South Africa and preponderance of mixed infections among ST53 isolates. *J. Clin. Microbiol*, **47**, 1848–1856 (2009).
34. Hanekom, M. *et al.* Population Structure of Mixed *Mycobacterium tuberculosis* Infection Is Strain Genotype and Culture Medium Dependent. *PLoS One*, **8**, 5–10 (2013).
35. Mulenga, C. *et al.* Diversity of *Mycobacterium tuberculosis* genotypes circulating in Ndola, Zambia. *BMC Infect. Dis.*, **10**, (2010).
36. Shin, S. S. *et al.* Mixed *Mycobacterium tuberculosis*-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. *J. Infect. Dis*, **218**, 1974–1982 (2018).

37. Zetola, N. M. *et al.* Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by genexpert MTB/RIF are associated with poor clinical outcomes. *J. Clin. Microbiol*, **52**, 2422–2429 (2014).
38. Vorkas, C. *et al.* Tuberculosis drug resistance and outcomes among tuberculosis inpatients in Lilongwe, Malawi. *Malawi Med. J*, **24**, 21–24 (2012).
39. Tuelo, M. *et al.* Genetic diversity of Mycobacterium tuberculosis strains circulating in Botswana, **4**, 1–14 (2019).
40. Perez-Lago. Co-infection with Drug-Susceptible and Reactivated Latent MDR Mtb - Letter. *Emerg. Infect. Dis*, **21**, 20–22 (2015).
41. Zamani, S. *et al.* Determination of circulating Mycobacterium tuberculosis strains and transmission patterns among TB patients in Iran, using 15 loci MIRU-VNTR. *Int. J. Mycobacteriology*, **4**, 119 (2015).
42. Tessema, B. *et al.* Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in Northwest Ethiopia: New phylogenetic lineages found in Northwest Ethiopia. *BMC Infectious Diseases* vol.13(2013).
43. Cohen, T. *et al.* Within-host heterogeneity of mycobacterium tuberculosis infection is associated with poor early treatment response: A prospective cohort study. *J. Infect. Dis*, **213**, 1796–1799 (2016).
44. Shin, S. S. *et al.* Advanced immune suppression is associated with increased prevalence of mixed-strain mycobacterium tuberculosis infections among persons at high risk for drug-resistant tuberculosis in Botswana. *J. Infect. Dis*, **211**, 347–351 (2015).
45. Elizabeth Glaser Foundation. *Strengthening the Tuberculosis and HIV / AIDS Response in the Southwest Region of Uganda (STAR-SW) Project.* (2015).

Figures

Figure 1

UPGMA tree based on the standard 24 loci MIRU-VNTR of isolates recovered from PTB patients in south western, Uganda.